Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haleon PLC Sponsored ADR ( (HLN) ) just unveiled an update.
On August 20, 2025, Haleon PLC announced a TR-1 notification regarding major holdings in the company. Wellington Management Group LLP, based in Boston, USA, has acquired or disposed of voting rights, resulting in a 5.01% total voting rights in Haleon. This change in holdings reflects a slight increase from previous notifications and may impact Haleon’s market positioning and stakeholder interests.
The most recent analyst rating on (HLN) stock is a Buy with a $10.95 price target. To see the full list of analyst forecasts on Haleon PLC Sponsored ADR stock, see the HLN Stock Forecast page.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.
Haleon PLC’s overall stock score of 65 reflects a mixed outlook. Strong financial performance and strategic investments are offset by bearish technical signals and regional sales challenges, particularly in North America. The company’s valuation is moderate, aligning with its growth prospects. Continued focus on innovation and market expansion could enhance its position, but near-term challenges need to be addressed.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC Sponsored ADR
Haleon PLC operates in the healthcare industry, focusing on consumer healthcare products. The company is known for its range of over-the-counter medications, oral health products, and nutritional supplements, serving a global market.
Average Trading Volume: 13,335,884
Technical Sentiment Signal: Buy
Current Market Cap: $43.56B
For an in-depth examination of HLN stock, go to TipRanks’ Overview page.